MANJARO Weight Loss Pen 2.5mg / 5mg / 7.5mg

Dual-target blood sugar control and weight loss; one injection per week for scientific management of weight and metabolism.

Product advantages

Advantage category: Tirzepatide Other GLP-1 single-receptor agonists (e.g. semaglutide, liraglutide)

Target Receptors GIP + GLP-1 dual receptor agonist GLP-1 receptor only

Blood Glucose-Lowering Effect More significant reduction in glycated haemoglobin (HbA1c) (clinical data shows a reduction of -2.0% or more) Typical reduction of -1.0% to -1.5%

Weight loss effect High dose (15 mg): average weight loss of 15%–20% over 72 weeks Typical weight loss of 10%–15%

Dosage frequency Once-weekly subcutaneous injection Also once-weekly (some require once-daily administration)

Effect on insulin secretion Dual enhancement of glucose-dependent insulin secretion Single pathway

Identifying Pain Points (Scenarios that resonate with target patients)

Target Population:

Type 2 diabetes patients with poor blood glucose control and overweight/obesity

Individuals with a BMI ≥27 and metabolic syndrome, including hypertension, hyperlipidaemia and fatty liver disease

😖 Take a handful of pills, yet blood sugar remains high

“I take several types of diabetes medication every day, yet my fasting blood sugar is still above 8.”

🍔 Repeated failed attempts at weight loss; gaining weight despite dieting

“I’ve tried dieting, exercise and meal replacement shakes, but the number on the scale just keeps going up.”

💉 Fear of injections, yet unwilling to take daily medication

“I’ve heard of a new weekly injection, but I’m worried about the side effects.”

📉 Blood sugar down, weight up (common with insulin secretagogues or insulin therapy)

“My blood sugar’s under control since starting insulin, but my waistline keeps expanding.”

🤢 GLP-1 monotherapy isn’t effective enough; doctors recommend combination therapy

“I’ve been on semaglutide for six months, but my weight has plateaued.”

Product Benefits

Key Ingredients/Mechanism Medical Benefits

Tirzepatide (GIP+GLP-1 dual agonist)

· Enhances postprandial insulin secretion and suppresses glucagon → Stabilises blood sugar and reduces fluctuations

· Slows gastric emptying and suppresses appetite → Naturally eats less, feels neither hungry nor craving food

· Promotes the browning of white fat → Increases energy expenditure, burns fat without losing muscle

Once-weekly subcutaneous injection : Reduces dosing frequency, improves adherence → No need to remember to take medication every day

Adjustable dosage (2.5mg–15mg) : Personalised treatment, with gradual dose escalation once tolerated → Manageable side effects, maximised efficacy

Product Features

Missed a dose? You can catch up on any day of the week without worrying

Starting at a low dose allows the body to adapt gradually, reducing nausea and vomiting

Easy to administer yourself; rotating injection sites minimises discomfort

Store in the fridge door, just like milk

An extra ‘fat-burning switch’ for stronger results

Product Information

Product Name: Tirzepatide Injection

Specifications:

· 2.5mg/0.5mL × 2 vials/box

· 5mg/0.5mL × 2 vials/box

· 7.5mg/0.5mL × 2 vials/box

Dosage Form: Solution for injection

Method of Administration:

· Subcutaneous injection once weekly; injection sites: abdomen, thigh or upper arm

· Initial dose: 2.5mg; dose may be increased every 4 weeks based on tolerability, up to a maximum of 15mg

· Injection may be administered on any day of the week; no fixed schedule required

Indications:

· To improve glycaemic control in patients with type 2 diabetes

· As an adjunct to weight loss in obese or overweight individuals with a BMI ≥27 and at least one weight-related condition (e.g. hypertension, hyperlipidaemia)

Active ingredient: Tirzepatide, a dual GIP and GLP-1 receptor agonist

Contraindications:

· Personal or family history of medullary thyroid carcinoma (MTC)

· Multiple endocrine neoplasia type 2 (MEN2)

· Patients with hypersensitivity to tirzepatide or any excipient

Common adverse reactions: nausea, vomiting, diarrhoea, loss of appetite (typically improving with continued use)

Special populations:

· Not recommended for use in pregnant or breastfeeding women; contraception is required during treatment

· Use with caution in patients with severe gastrointestinal disorders (e.g. gastroparesis)

Storage conditions: Protect from light; store refrigerated at 2–8°C; do not freeze

Important note: This is a prescription-only medicine and must be used under medical supervision; do not adjust the dose or discontinue treatment without consulting a doctor

The following data are derived from the key Phase III clinical trials of tirzepatide (SURPASS and SURMOUNT series); the source must be cited when referencing.

Glucose-lowering effects:

· In patients with type 2 diabetes, 40 weeks of treatment with 15 mg tirzepatide resulted in an average reduction in HbA1c of 2.0%–2.3% (compared with 1.9% for semaglutide).

· Over 50% of patients achieved HbA1c levels below 5.7% (within the normal range).

Weight loss effects:

· SURMOUNT-1 study (obese patients without diabetes): over 72 weeks, the 15 mg group achieved an average weight loss of 20.9% (approximately 22.5 kg).

· SURMOUNT-2 study (obese patients with type 2 diabetes): over 72 weeks, the 15 mg group achieved an average weight loss of 14.7%.

Cardiovascular benefits:

· Exploratory analyses indicate that tirzopentide reduces systolic blood pressure by 5–8 mmHg and improves triglyceride and very-low-density lipoprotein levels.

Tolerability:

· The most common adverse reactions were gastrointestinal (nausea in approximately 20% and diarrhoea in approximately 15%), mostly mild to moderate in severity and resolved with dose titration.

· The discontinuation rate due to adverse events was approximately 7%–10%, comparable to other GLP-1 agonists.

Data Highlights

📉 HbA1c reduced by up to 2.3%

⚖️ Weight reduced by up to 20.9%

💉 Once weekly, with gradual dose escalation

🛡️ Improves blood pressure and lipid profiles

Brand Introduction

Brand Name: Weight Loss Injection

The Weight Loss Injection Metabolic Medicine range specialises in innovative treatments targeting the gastrointestinal-pancreatic (GIP) pathway. Tirzepatide is the first GIP/GLP-1 dual receptor agonist we have introduced; it was developed by a leading international pharmaceutical company and validated through rigorous clinical trials.

We do not promise ‘instant weight loss with a single injection’; we only promise evidence-based efficacy and safety. We firmly believe that medical weight loss is not about torturing oneself with willpower, but about using scientific tools to restore metabolism to its proper course.

From blood sugar to body weight, from metabolism to health—we leave no target unaddressed.

No longer do you have to fight obesity and high blood sugar alone; with one injection a week, you will see the difference.